{
 "generated": "2026-11-18T09:58:08-08:00",
 "source": "product/entities/jurisdictions.csv",
 "lines": [
  {
   "geo": "geo:US",
   "name": "United States",
   "level": "country",
   "cc": "US",
   "drug": "psilocybin",
   "status": "Psilocybin and psilocyn are Schedule I controlled substances under federal law (21 CFR 1308.11(d)).",
   "src": "https://www.ecfr.gov/current/title-21/section-1308.11",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US",
   "name": "United States",
   "level": "country",
   "cc": "US",
   "drug": "MDMA",
   "status": "MDMA is a Schedule I controlled substance under federal law (21 CFR 1308.11(d)).",
   "src": "https://www.ecfr.gov/current/title-21/section-1308.11",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US",
   "name": "United States",
   "level": "country",
   "cc": "US",
   "drug": "LSD",
   "status": "LSD is a Schedule I controlled substance under federal law (21 CFR 1308.11(d)).",
   "src": "https://www.ecfr.gov/current/title-21/section-1308.11",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US",
   "name": "United States",
   "level": "country",
   "cc": "US",
   "drug": "DMT",
   "status": "DMT is a Schedule I controlled substance under federal law (21 CFR 1308.11(d)).",
   "src": "https://www.ecfr.gov/current/title-21/section-1308.11",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US",
   "name": "United States",
   "level": "country",
   "cc": "US",
   "drug": "ibogaine",
   "status": "Ibogaine is a Schedule I controlled substance under federal law (21 CFR 1308.11(d)).",
   "src": "https://www.ecfr.gov/current/title-21/section-1308.11",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US",
   "name": "United States",
   "level": "country",
   "cc": "US",
   "drug": "mescaline",
   "status": "Mescaline and peyote are Schedule I controlled substances under federal law (21 CFR 1308.11(d)).",
   "src": "https://www.ecfr.gov/current/title-21/section-1308.11",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US",
   "name": "United States",
   "level": "country",
   "cc": "US",
   "drug": "ketamine",
   "status": "Ketamine is Schedule III (21 CFR 1308.13(c)) and FDA-labeled for anesthesia; psychiatric use is off-label, which FDA says prescribers generally may do when medically appropriate.",
   "src": "https://www.ecfr.gov/current/title-21/section-1308.13",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US",
   "name": "United States",
   "level": "country",
   "cc": "US",
   "drug": "esketamine",
   "status": "Spravato (esketamine) is FDA-approved for adults with treatment-resistant depression; its REMS limits use to certified healthcare settings with at least 2 hours of monitoring.",
   "src": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed",
   "program": "Spravato REMS (FDA)",
   "program_src": "https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=386",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US-OR",
   "name": "Oregon",
   "level": "state",
   "cc": "US",
   "region": "Oregon",
   "drug": "psilocybin",
   "status": "Adults 21+ may buy and consume psilocybin only during a supervised session at an OHA-licensed service center (ORS 475A); no prescription is required.",
   "src": "https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Access-Psilocybin-Services.aspx",
   "program": "Oregon Psilocybin Services (OHA, ORS 475A)",
   "program_src": "https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US-CO",
   "name": "Colorado",
   "level": "state",
   "cc": "US",
   "region": "Colorado",
   "drug": "psilocybin",
   "status": "Adults 21+ may receive psilocybin or psilocyn services from a licensed facilitator at a state-licensed healing center under the Natural Medicine Health Act (C.R.S. 12-170).",
   "src": "https://content.leg.colorado.gov/sites/default/files/documents/2023A/bills/sl/2023a_sl_249.pdf",
   "program": "Colorado Natural Medicine Program (healing centers and facilitators)",
   "program_src": "https://content.leg.colorado.gov/sites/default/files/documents/2023A/bills/sl/2023a_sl_249.pdf",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US-CO",
   "name": "Colorado",
   "level": "state",
   "cc": "US",
   "region": "Colorado",
   "drug": "DMT",
   "status": "DMT can join Colorado's licensed program only on advisory-board recommendation and state approval on or after June 1, 2026; adults 21+ may possess and share it for unpaid personal use.",
   "src": "https://content.leg.colorado.gov/sites/default/files/documents/2023A/bills/sl/2023a_sl_249.pdf",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US-CO",
   "name": "Colorado",
   "level": "state",
   "cc": "US",
   "region": "Colorado",
   "drug": "mescaline",
   "status": "Mescaline (not peyote) can join Colorado's licensed program only on board recommendation and state approval on or after June 1, 2026; adults 21+ may possess it for unpaid personal use.",
   "src": "https://content.leg.colorado.gov/sites/default/files/documents/2023A/bills/sl/2023a_sl_249.pdf",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US-CO",
   "name": "Colorado",
   "level": "state",
   "cc": "US",
   "region": "Colorado",
   "drug": "ibogaine",
   "status": "As of July 2026 ibogaine awaited state approval for Colorado healing centers; HB26-1325 authorizes ibogaine rules and a donor-funded pilot. Adults 21+ may possess it for unpaid personal use.",
   "src": "https://leg.colorado.gov/bill_files/117336/download",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:US-NM",
   "name": "New Mexico",
   "level": "state",
   "cc": "US",
   "region": "New Mexico",
   "drug": "psilocybin",
   "status": "The Medical Psilocybin Act (in force June 20, 2025) requires NMDOH to run a medical program by Dec 31, 2027; patient and clinic rules were still proposed at an Oct 2, 2026 hearing.",
   "src": "https://www.nmlegis.gov/Sessions/25%20Regular/final/SB0219.pdf",
   "program": "Medical Psilocybin Program (NMDOH)",
   "program_src": "https://www.nmhealth.org/about/mcpp/mpp/",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:NL",
   "name": "Netherlands",
   "level": "country",
   "cc": "NL",
   "drug": "psilocybin",
   "status": "Psilocybin (Opium Act List I) and psilocybin mushrooms (List II) are controlled; truffles (sclerotia) are not listed, and the government has called them legal products (2011).",
   "src": "https://wetten.overheid.nl/BWBR0001941/",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:MX",
   "name": "Mexico",
   "level": "country",
   "cc": "MX",
   "drug": "psilocybin",
   "status": "Psilocybin and hallucinogenic mushrooms are controlled (General Health Law art. 245); possession for recognized Indigenous or Afro-Mexican community ceremonies is not prosecuted (CPF art. 195 bis).",
   "src": "https://www.diputados.gob.mx/LeyesBiblio/pdf/LGS.pdf",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:MX",
   "name": "Mexico",
   "level": "country",
   "cc": "MX",
   "drug": "ibogaine",
   "status": "Ibogaine is not on the controlled-substance lists of Mexico's General Health Law (arts. 234 and 245, as amended to January 2026).",
   "src": "https://www.diputados.gob.mx/LeyesBiblio/pdf/LGS.pdf",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:BS",
   "name": "The Bahamas",
   "level": "country",
   "cc": "BS",
   "drug": "psilocybin",
   "status": "Psilocybine and psilocine are listed in the Dangerous Drugs Act (Application) Order 1994, which applies Part IV of the Dangerous Drugs Act (Ch. 228) to them.",
   "src": "http://laws.bahamas.gov.bs/cms/images/LEGISLATION/SUBORDINATE/1994/1994-0077/1994-0077.pdf",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:CA",
   "name": "Canada",
   "level": "country",
   "cc": "CA",
   "drug": "psilocybin",
   "status": "Psilocybin is controlled in Canada; Health Canada allows access only through authorized clinical trials, Special Access Program requests by practitioners, or case-by-case s.56(1) exemptions.",
   "src": "https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html",
   "program": "Special Access Program (Health Canada)",
   "program_src": "https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:CA",
   "name": "Canada",
   "level": "country",
   "cc": "CA",
   "drug": "MDMA",
   "status": "MDMA is a restricted drug in Canada; practitioners may request it case by case through Health Canada's Special Access Program for serious or life-threatening conditions when other treatments fail.",
   "src": "https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html",
   "program": "Special Access Program (Health Canada)",
   "program_src": "https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:CZ",
   "name": "Czech Republic",
   "level": "country",
   "cc": "CZ",
   "drug": "psilocybin",
   "status": "Since 1 Jan 2026, specialist doctors may prescribe and give compounded psilocybin for severe or cancer-related depression after standard treatment fails, under dose and supervision limits.",
   "src": "https://e-sbirka.gov.cz/sbr-cache/dokumenty-sbirky/%2Fsb%2F2025%2F552%2F2026-01-01/fragmenty?cisloStranky=0",
   "program": "Therapeutic psilocybin (Act 270/2025 Sb.)",
   "program_src": "https://mzd.gov.cz/wp-content/uploads/2025/12/Prehled-zmen-zdravotnicke-legislativy-od-ledna-2026.pdf",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:DE",
   "name": "Germany",
   "level": "country",
   "cc": "DE",
   "drug": "psilocybin",
   "status": "BfArM lists a confirmed compassionate-use (hardship) program for psilocybin in treatment-resistant depression, run by ZI Mannheim and valid until 17 June 2027.",
   "src": "https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Compassionate-Use/compUse-tabelle.html?nn=701486",
   "program": "Compassionate-use program (BfArM, Härtefallprogramm)",
   "program_src": "https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Compassionate-Use/compUse-tabelle.html?nn=701486",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:CH",
   "name": "Switzerland",
   "level": "country",
   "cc": "CH",
   "drug": "psilocybin",
   "status": "FOPH may grant a treating doctor a per-patient exceptional licence for limited medical use of psilocybin, a banned narcotic, when other therapies are exhausted (Art. 8(5) NarcA).",
   "src": "https://www.bag.admin.ch/en/limited-medical-use-of-banned-narcotics",
   "program": "Exceptional licences for limited medical use (FOPH, Art. 8(5) NarcA)",
   "program_src": "https://www.bag.admin.ch/en/limited-medical-use-of-banned-narcotics",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:CH",
   "name": "Switzerland",
   "level": "country",
   "cc": "CH",
   "drug": "MDMA",
   "status": "FOPH may grant a treating doctor a per-patient exceptional licence for limited medical use of MDMA, a banned narcotic, when other therapies are exhausted (Art. 8(5) NarcA).",
   "src": "https://www.bag.admin.ch/en/limited-medical-use-of-banned-narcotics",
   "program": "Exceptional licences for limited medical use (FOPH, Art. 8(5) NarcA)",
   "program_src": "https://www.bag.admin.ch/en/limited-medical-use-of-banned-narcotics",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:CH",
   "name": "Switzerland",
   "level": "country",
   "cc": "CH",
   "drug": "LSD",
   "status": "FOPH may grant a treating doctor a per-patient exceptional licence for limited medical use of LSD, a banned narcotic, when other therapies are exhausted (Art. 8(5) NarcA).",
   "src": "https://www.bag.admin.ch/en/limited-medical-use-of-banned-narcotics",
   "program": "Exceptional licences for limited medical use (FOPH, Art. 8(5) NarcA)",
   "program_src": "https://www.bag.admin.ch/en/limited-medical-use-of-banned-narcotics",
   "as_of": "2026-10-04"
  },
  {
   "geo": "geo:NZ",
   "name": "New Zealand",
   "level": "country",
   "cc": "NZ",
   "drug": "psilocybin",
   "status": "Medsafe can approve individual practitioners under reg. 22 of the Misuse of Drugs Regulations 1977 to prescribe, supply and administer psychedelics such as psilocybin outside research.",
   "src": "https://www.medsafe.govt.nz/profs/psychedelics.asp",
   "program": "Medsafe approvals (reg. 22, Misuse of Drugs Regulations)",
   "program_src": "https://www.medsafe.govt.nz/profs/psychedelics.asp",
   "as_of": "2026-10-04"
  }
 ]
}